Last reviewed · How we verify
Comparator: Tripedia
Tripedia is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.
Tripedia is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | Comparator: Tripedia |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Inactivated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Tripedia contains inactivated toxoids of Corynebacterium diphtheriae and Clostridium tetani, along with acellular pertussis antigens (proteins from Bordetella pertussis). These components trigger adaptive immune responses that generate protective antibodies and cellular immunity against these three bacterial diseases. The vaccine is administered intramuscularly and is typically given as part of the standard childhood immunization schedule.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Fussiness/irritability
- Drowsiness
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
- Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (PHASE2)
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults (PHASE1)
- Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants (PHASE3)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PHASE3)
- Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Tripedia CI brief — competitive landscape report
- Comparator: Tripedia updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI